Serum Institute to make Novavax’s COVID-19 shots after FDA’s approval
Category: #healthcare  By Mateen Dalal  Date: 2022-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Serum Institute to make Novavax’s COVID-19 shots after FDA’s approval

Novavax Inc. has announced that its COVID-19 adult vaccine (NVX-CoV2373) which is expected to be used in the U.S. after receiving the approval from the Food and Drug Administration (FDA), would be produced by the Serum Institute of India (SII).

All commercially distributed vaccines are being made in a single facility by the Serum Institute of India which includes the vaccines that are being deployed around the world as well as the ones that will be initially distributed in the U.S., according to Filip Dubovsky, Novavax's Chief Medical Officer.

Novavax revealed that it has achieved a major milestone on its path with an emergency use authorization from the U.S. Food and Drug Administration (USFDA). Following the successful completion of an inspection of the manufacturing site at SII, a meeting with the Vaccines and Related Biological Products Advisory Committee (VRBPAC) was scheduled for 7th June.

After the VRBPAC suggested the USFDA grant emergency use authorization (EUA) for Novavax's COVID-19 vaccine for adults over the age of 18, the U.S. biotechnology major’s shared jumped by 20% during the intraday trading, pushing the company one step closer to launching in the United States. The VRBPAC voted 21 to 0 in support of the vaccination, with one abstention, according to Novavax's official website.

Meanwhile, SII is preparing to work on an Omicron variant-specific vaccination for COVID-19 with its U.S. partner Novavax, which is expected to differ from the original shot developed by the US giant using the Wuhan strain of the Sars-CoV-2 virus.

The Pune-based company has also received approval from the Indian drug regulator's office to commence manufacturing trial batches of this vaccine for testing purposes. It is worth noting that Novavax is developing monovalent and bivalent Omicron-specific vaccines, both of which will soon undergo clinical trials.

Source Credit:

https://www.business-standard.com/article/companies/india-s-serum-institute-to-make-novavax-s-covid-vaccine-for-us-market-122060900042_1.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Eastern China strengthens COVID-19 restrictions as new clusters arise
Eastern China strengthens COVID-19 restrictions as new clusters arise
By Mateen Dalal

Amid steady economic recovery under the country’s stringent zero-Covid-19 policy, cities in Ea...

Monkeypox virus found to be mutating faster than expected: Report
Monkeypox virus found to be mutating faster than expected: Report
By Mateen Dalal

Researchers studying the genetic nature of the monkeypox have recently claimed that the virus has be...

Bristol Myers Squibb to face USD 6.4 billion lawsuit over delayed drug
Bristol Myers Squibb to face USD 6.4 billion lawsuit over delayed drug
By Mateen Dalal

A U.S. judge has reportedly refused to toss out a USD 6.4 billion lawsuit that claimed pharma giant ...